 |
|
|
| |
Simeprevir (TMC435) with peginterferon-α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy in patients with genotype 1b HCV in the PROMISE Phase III trial
|
| |
| |
Reported by Jules Levin
APASL 2014 March 12-15 Brisbane, Australia
EJ Gane,1 X Forns,2 E Lawitz,3 S Zeuzem,4 JP Bronowicki,5 P Andreone,6 A Horban,7 AS Brown,8 M Peeters,9 O Lenz,9 S Ouwerkerk-Mahadevan,9 R Kalmeijer,10 G De La Rosa,1 R Sinha,9 M Beumont-Mauviel9
1Auckland Hospital Clinical Studies Unit, Auckland, New Zealand; 2Liver Unit, Hospital Clinic, IDIBAPS, CIBEREHD, Barcelona, Spain; 3Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 4J.W. Goethe University Hospital, Frankfurt, Germany; 5INSERM U954, Universite de Lorraine, Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France; 6Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Italy; 7Medical University of Warsaw, Wolska, Warsaw, Poland; 8Imperial College Healthcare NHS Trust, London, UK; 9Janssen Infectious Diseases BVBA and Janssen Research & Development, Beerse, Belgium;10Janssen Global Services, LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
